Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 02:05 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Trial to Compare Efficacy and Safety of Follitropin Delta Versus Placebo (Inactive Treatment) in the Treatment of Men With Idiopathic Infertility (Unexplained Reduction of Semen Quality) (ADAM)
NCT05403476 · Ferring Pharmaceuticals · PHASE2 · terminated · last registry update 2026-08-28 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “The probability of enrolling subjects in the trial in a reasonable timeframe was too low. The termination was not due to safety concerns nor changes in Ferring's Reproductive Medicine strategy or interest in developing treatments for Male Infertility” | – | Registry record, Ferring Pharmaceuticals |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against FSHR within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-10-29Also stopped (withdrawn): American Hospital 2 Kosovo, Follicle-stimulating hormone (FSH) + Follicle-stimulating hormone (FSH) (NCT07346235)
- 2026-10-29Also stopped (withdrawn): Azienda Sanitaria Locale Bari, Follicle Stimulating Hormone (NCT02275169)
- 2026-10-13Also stopped (terminated): Universitair Ziekenhuis Brussel, a drug against FSHR (NCT03686852)
- 2026-09-11Phase 3 first posted: Fundación para la Investigación del Hospital Clínico de Valencia, Human chorionic gonadotropin (hCG) + Follitropin delta (NCT07816562)
- 2026-03-30Also stopped (terminated): Ferring Pharmaceuticals, FE 999302 + Follitropin delta (NCT06511791)
- 2026-03-30Also stopped (terminated): Ferring Pharmaceuticals, Follitropin delta + FE999302 (NCT06466486)
- 2026-02-12Results posted on the registry: Ferring Pharmaceuticals, FE 999049 + GONAL-F (NCT06173869)
- 2026-01-16Phase 3 first posted: American Hospital 2 Kosovo, Follicle-stimulating hormone (FSH) + Follicle-stimulating hormone (FSH) (NCT07346235)
- 2026-01-14Phase 3 first posted: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany, Follitropin alfa/lutropin alfa (MBJ-0011) + hMG (NCT07340827)
- 2025-12-09Results posted on the registry: Memorial Sloan Kettering Cancer Center, Vagifem® (vaginal 17β-estradiol) questionnaire & menopause symptom checklist (NCT00984399)
- 2025-10-15Phase 3 first posted: Granata Bio Corporation, hMG subcutaneous injection + Placebo (NCT07216742)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision